HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this link to a friend Similar articles in this journal Add article to my folders Download to citation manager Request Permissions Google Scholar Articles by Lindsay, A. PubMed Articles by Lindsay, A.

JournalScan

The first 150 words of the full text of this article appear below.

	INTERVENTIONAL CARDIOLOGY

 
MULTISTRATEGY: tirofiban and sirolimus in primary PCI
In patients undergoing primary percutaneous coronary intervention, the use of abciximab has been shown to improve ST-segment resolution and to reduce mortality in comparison with placebo. Subsequently, the TARGET (Do Tirofiban and Reo-Pro Give Similar Efficacy) trial, a head-to-head comparison of abciximab against tirofiban, suggested that the former was the more effective of the two drugs, but it was noted that the bolus dose of tirofiban used in the trial was low (10 µg/kg). Therefore the MULTISTRATEGY trial was primarily designed to compare the efficacy of the two drugs when using a more appropriate dose of tirofiban. In addition, as patients with ST-segment elevation myocardial infarction (STEMI) are thought to be at a higher risk for stent thrombosis, patients underwent a second randomisation to either a sirolimus-eluting or non-drug-eluting stent.

An open-label, 2x2 factorial study of 745 patients with STEMI was performed across 16 centres in Italy, Spain . . . [Full text of this article]